BMSN. Latest HemaXellerate News
08:12 EDT 21st October 2013 | BioPortfolio
Home » Topics » HemaXellerate » Latest News
What is it?Latest NewsClinical TrialsResearchDrugsReportsCorporate
Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I Covering Aplastic Anemia
SAN DIEGO, CA -- (Marketwired) -- 09/26/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today its subsidiary Regen BioPharma Inc. signed an agreement with Dr. Wei-Ping Min covering experiments requested by the FDA in support of clearance for the company's IND #15376 for use of HemaXellerate I in the treatment of drug refractory aplastic anemia. Regen BioPharma filed an Investigati...
Bio-Matrix Scientific Group's Subsidiary, Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
SAN DIEGO, CA -- (Marketwired) -- 09/25/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its Regen BioPharma subsidiary is currently developing research plans for its breast cancer immunotherapeutic product, dCellVax. This cell therapy is based on patent # 8,389,708 obtained from Dr. Wei-Ping Min of the University of Western Ontario as well as an international patent port...
Chemotherapy Induced Anemia - Pipeline Review, H2 2013
Recently added to the BioPortfolio report store, Chemotherapy Induced Anemia - Pipeline Review, H2 2013 is a new report from Global Markets Direct published on 2013-09-19. This 51-page report is available in PDF from $2000. Chemotherapy Induced Anemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2013', provides an overview of th...
Mom’s Meals Insights: Don’t Let Anemia Hamper Your Overall Health
A recent study showed seniors with anemia might be at higher risk for dementia. A diet filled with iron-rich foods may be a good idea for anemia and overall health. Des Moines, IA (PRWEB) September 17, 2013 A recent study conducted by researchers from the University of California, San Francisco, showed that seniors with anemia might be at higher risk for dementia. Over 2500 people in their 70’s...
Anemia - Pipeline Review, H2 2013
Recently added to the BioPortfolio report store, Anemia - Pipeline Review, H2 2013 is a new report from Global Markets Direct published on 2013-08-29. This 329-page report is available in PDF from $2000. Anemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides in...
Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation
Medical Food Designed to Address the Increased Nutritional Requirements of Anemia Los Angeles, CA (PRWEB) September 04, 2013 Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the company has initiated a third open-label clinical trial of its oral amino acid-based erythropoietin stimulating system (ESS) to determine increased red blood cell production in subjects diagnosed with anemia...
Heavy Drinking Can Cause Anemia And Dementia
A new study finds that heavy alcohol consumption can lead to both anemia and dementia. Anyone suffering from alcohol abuse should contact a professional detox center like Harbor Village. Miami, Florida (PRWEB) August 08, 2013 As reported by Fox News on 8/1 titled "Anemia may put people at higher risk for dementia," a new research study published in the journal Neurology finds that peopl...
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 07/31/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on its subsidiary, Regen BioPharma's Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA) covering the HemaXellerate I? stem cell product for treatment of drug refractory aplastic anemia. "We are currently in the second round of d...
Aplastic Anemia - Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Aplastic Anemia - Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-06-29. This 37-page report is available in PDF from $2000. Aplastic Anemia - Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Aplastic Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipelin...
Anemia Partnering 2007-2013 Edition: 1
Recently added to the BioPortfolio report store, Anemia Partnering 2007-2013 Edition: 1 is a new report from Current Partnering published on 2013-06-30. This 100+-page report is available in PDF from $995. Summary:The Anemia Partnering 2007-2013 report provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies. Trends i...
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 06/07/13 -- Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments...
Iron Deficiency Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Iron Deficiency Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-04-29. This 67-page report is available in PDF from $2000. Iron Deficiency Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Iron Deficiency Anemia - Pipeline Review, H2 2013', provides an overview of the indicatio...
Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
SAN DIEGO, CA -- (Marketwired) -- 04/04/13 -- Regen BioPharma, Inc. (Regen), a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), provided an update on the Company's progress with HemaXellerate and other new developments. Currently, Regen is focused on two core areas: a)The HemaXellerate Program, which is based on treating disorders of blood production; and b) Our cancer...
Chemotherapy Induced Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Chemotherapy Induced Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-03-17. This 53-page report is available in PDF from $2000. Chemotherapy Induced Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H1 2013', provides an overview o...
Renal Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Renal Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-03-17. This 118-page report is available in PDF from $2000. Renal Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Renal Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. T...
Regen BioPharma Receives IND # From FDA for HemaXellerate
SAN DIEGO, CA -- (Marketwire) -- 03/18/13 -- Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia. As part of the clinical trial approval process, the FDA will issue com...
Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-02-27. This 119-page report is available in PDF from $2000. Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provide...
Anemia Partnering 2007-2013 Edition: 1 Code: CP2207ane
Recently added to the BioPortfolio report store, Anemia Partnering 2007-2013 Edition: 1 Code: CP2207ane is a new report from Current Partnering published on 2012-12-31. This 100+-page report is available in PDF from $995. The Anemia Partnering 2007-2013 report provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies....
Affymax, Takeda Recall Anemia Drug
WASHINGTON -- Drug companies Affymax Inc. and Takeda Pharmaceutical Co. have issued a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients, including some deaths. The companies said that more than 25,000 patients have received Omontys, which is used against anemia in patients undergoing kidney dialysis. The companies said that 0.2% of...
FDA alerts health care providers of recall of anemia drug Omontys
The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill., due to reports of anaphylaxis, a serious and life-threatening allergic reaction. Omontys is used to treat anemia in adult dialysis patients.
Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem's PLacental eXpanded (PLX) cells orphan drug status for the treatment of aplastic anemia. Orphan drug designation qualifies a company for several ben...
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia
SAN DIEGO, CA -- (Marketwire) -- 02/05/13 -- Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate I? stem cell drug in patients with drug-refractory aplastic anemia. HemaXellerate I? is a patient-spec...
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
SAN DIEGO, CA -- (Marketwire) -- 01/24/13 -- Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate? bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content...10-231.pdf. The publication...
Aplastic Anemia – Pipeline Review, H2 2012
Recently added to the BioPortfolio report store, Aplastic Anemia – Pipeline Review, H2 2012 is a new report from Global Markets Direct published on 2012-12-25. This 110-page report is available in PDF from $2000. Aplastic Anemia – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Aplastic Anemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pi...
FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease (pdf 66KB)
Home » Topics » HemaXellerate » Latest News
Biotech & Healthcare Channels World News Life Science Events Corporate Database Market Reports Categories
Search BioPortfolio:
BMSN
08:12 EDT 21st October 2013 | BioPortfolio
Home » Topics » HemaXellerate » Latest News
What is it?Latest NewsClinical TrialsResearchDrugsReportsCorporate
Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I Covering Aplastic Anemia
SAN DIEGO, CA -- (Marketwired) -- 09/26/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today its subsidiary Regen BioPharma Inc. signed an agreement with Dr. Wei-Ping Min covering experiments requested by the FDA in support of clearance for the company's IND #15376 for use of HemaXellerate I in the treatment of drug refractory aplastic anemia. Regen BioPharma filed an Investigati...
Bio-Matrix Scientific Group's Subsidiary, Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
SAN DIEGO, CA -- (Marketwired) -- 09/25/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its Regen BioPharma subsidiary is currently developing research plans for its breast cancer immunotherapeutic product, dCellVax. This cell therapy is based on patent # 8,389,708 obtained from Dr. Wei-Ping Min of the University of Western Ontario as well as an international patent port...
Chemotherapy Induced Anemia - Pipeline Review, H2 2013
Recently added to the BioPortfolio report store, Chemotherapy Induced Anemia - Pipeline Review, H2 2013 is a new report from Global Markets Direct published on 2013-09-19. This 51-page report is available in PDF from $2000. Chemotherapy Induced Anemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2013', provides an overview of th...
Mom’s Meals Insights: Don’t Let Anemia Hamper Your Overall Health
A recent study showed seniors with anemia might be at higher risk for dementia. A diet filled with iron-rich foods may be a good idea for anemia and overall health. Des Moines, IA (PRWEB) September 17, 2013 A recent study conducted by researchers from the University of California, San Francisco, showed that seniors with anemia might be at higher risk for dementia. Over 2500 people in their 70’s...
Anemia - Pipeline Review, H2 2013
Recently added to the BioPortfolio report store, Anemia - Pipeline Review, H2 2013 is a new report from Global Markets Direct published on 2013-08-29. This 329-page report is available in PDF from $2000. Anemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides in...
Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation
Medical Food Designed to Address the Increased Nutritional Requirements of Anemia Los Angeles, CA (PRWEB) September 04, 2013 Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the company has initiated a third open-label clinical trial of its oral amino acid-based erythropoietin stimulating system (ESS) to determine increased red blood cell production in subjects diagnosed with anemia...
Heavy Drinking Can Cause Anemia And Dementia
A new study finds that heavy alcohol consumption can lead to both anemia and dementia. Anyone suffering from alcohol abuse should contact a professional detox center like Harbor Village. Miami, Florida (PRWEB) August 08, 2013 As reported by Fox News on 8/1 titled "Anemia may put people at higher risk for dementia," a new research study published in the journal Neurology finds that peopl...
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 07/31/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on its subsidiary, Regen BioPharma's Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA) covering the HemaXellerate I? stem cell product for treatment of drug refractory aplastic anemia. "We are currently in the second round of d...
Aplastic Anemia - Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Aplastic Anemia - Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-06-29. This 37-page report is available in PDF from $2000. Aplastic Anemia - Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Aplastic Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipelin...
Anemia Partnering 2007-2013 Edition: 1
Recently added to the BioPortfolio report store, Anemia Partnering 2007-2013 Edition: 1 is a new report from Current Partnering published on 2013-06-30. This 100+-page report is available in PDF from $995. Summary:The Anemia Partnering 2007-2013 report provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies. Trends i...
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
SAN DIEGO, CA -- (Marketwired) -- 06/07/13 -- Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments...
Iron Deficiency Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Iron Deficiency Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-04-29. This 67-page report is available in PDF from $2000. Iron Deficiency Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Iron Deficiency Anemia - Pipeline Review, H2 2013', provides an overview of the indicatio...
Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
SAN DIEGO, CA -- (Marketwired) -- 04/04/13 -- Regen BioPharma, Inc. (Regen), a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), provided an update on the Company's progress with HemaXellerate and other new developments. Currently, Regen is focused on two core areas: a)The HemaXellerate Program, which is based on treating disorders of blood production; and b) Our cancer...
Chemotherapy Induced Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Chemotherapy Induced Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-03-17. This 53-page report is available in PDF from $2000. Chemotherapy Induced Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H1 2013', provides an overview o...
Renal Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Renal Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-03-17. This 118-page report is available in PDF from $2000. Renal Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Renal Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. T...
Regen BioPharma Receives IND # From FDA for HemaXellerate
SAN DIEGO, CA -- (Marketwire) -- 03/18/13 -- Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia. As part of the clinical trial approval process, the FDA will issue com...
Anemia – Pipeline Review, H1 2013
Recently added to the BioPortfolio report store, Anemia – Pipeline Review, H1 2013 is a new report from Global Markets Direct published on 2013-02-27. This 119-page report is available in PDF from $2000. Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provide...
Anemia Partnering 2007-2013 Edition: 1 Code: CP2207ane
Recently added to the BioPortfolio report store, Anemia Partnering 2007-2013 Edition: 1 Code: CP2207ane is a new report from Current Partnering published on 2012-12-31. This 100+-page report is available in PDF from $995. The Anemia Partnering 2007-2013 report provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies....
Affymax, Takeda Recall Anemia Drug
WASHINGTON -- Drug companies Affymax Inc. and Takeda Pharmaceutical Co. have issued a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients, including some deaths. The companies said that more than 25,000 patients have received Omontys, which is used against anemia in patients undergoing kidney dialysis. The companies said that 0.2% of...
FDA alerts health care providers of recall of anemia drug Omontys
The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill., due to reports of anaphylaxis, a serious and life-threatening allergic reaction. Omontys is used to treat anemia in adult dialysis patients.
Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem's PLacental eXpanded (PLX) cells orphan drug status for the treatment of aplastic anemia. Orphan drug designation qualifies a company for several ben... Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia
SAN DIEGO, CA -- (Marketwire) -- 02/05/13 -- Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate I? stem cell drug in patients with drug-refractory aplastic anemia. HemaXellerate I? is a patient-spec...
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
SAN DIEGO, CA -- (Marketwire) -- 01/24/13 -- Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate? bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content...10-231.pdf. The publication...
Aplastic Anemia – Pipeline Review, H2 2012
Recently added to the BioPortfolio report store, Aplastic Anemia – Pipeline Review, H2 2012 is a new report from Global Markets Direct published on 2012-12-25. This 110-page report is available in PDF from $2000. Aplastic Anemia – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Aplastic Anemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pi...
FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease (pdf 66KB)
Home » Topics » HemaXellerate » Latest News
Biotech & Healthcare Channels World News Life Science Events Corporate Database Market Reports Categories
Search BioPortfolio:
BMSN
